Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMRKXPT)

Drug Name
Ketoprofen Drug Info
Synonyms
Actron; Alrheumat; Alrheumum; Alrheumun; Aneol; Capisten; Dexal; Epatec; Fastum; Kefenid; Ketoprofene; Ketoprofeno; Ketoprofenum; Ketopron; Ketoprophene; Lertus; Menamin; Meprofen; Orudis; Orugesic; Oruvail; Oscorel; Profenid; Toprec; Toprek; Benzoylhydratropic Acid; Orudis KT; K 1751; RP 19583; RP19583; RU 4733; Arthril (TN); Fastum (TN); Fastum Gel (TN); Iso-K; Keto (TN); Ketoflam (TN); Ketomex (TN); Ketonal (TN); Ketoprofenas (TN); Ketoprofene (TN); Ketoprofene [INN-French]; Ketoprofeno [INN-Spanish]; Ketoprofenum (TN); Ketoprofenum [INN-Latin]; Ketorin (TN); Ketospray (TN); Lasonil (TN); M-Benzoylhydratropic acid; Oki (TN); Orudis (TN); Oruvail (TN); RP-19583; Racemic-Ketoprofen; Zon (TN); Bi-Profnid (TN); RP, 19,583; Ketoprofen (JP15/USP/INN); Ketoprofen [USAN:INN:BAN:JAN]; Orudis, Oruvail, Ketoflam, Orudis KT, Ketoprofen; Acide (benzoyl-3-phenyl)-2-propionique; Acide (benzoyl-3-phenyl)-2-propionique [French]; L'Acide (benzoyl-3-phenyl)-2-propionique; (+-)-m-Benzoylhydratropic acid; 2-(3-Benzoylphenyl)propanoic acid; 2-(3-Benzoylphenyl)propionic acid; 2-(m-Benzoylphenyl)propionic acid; 2-[3-(benzoyl)phenyl]propanoic acid; 2-[3-(phenylcarbonyl)phenyl]propanoic acid; 2-[3-Benzoylphenyl]propionic acid; 3-Benzoylhydratropic acid
Therapeutic ClassAnalgesics
Cross-matching ID
PubChem CID
3825
ChEBI ID
CHEMBL571
CAS Number
CAS 22071-15-4
TTD Drug ID
D0W9WF
VARIDT Drug ID
DR00690
INTEDE Drug ID
DR0907
ACDINA Drug ID
D00343

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Cell cycle 1.94 3.31e-2 110/124 (88.71%) PCNA;CDKN1B;E2F2;...
Valine, leucine and isoleucine degradation 1.84 4.30e-2 42/48 (87.5%) HMGCS1;DLD;BCAT1;...
Ether lipid metabolism -1.65 3.08e-2 32/49 (65.31%) PLA2G7;CHPT1;PLPP1;...
Graft-versus-host disease -1.66 3.14e-2 32/42 (76.19%) IFNG;HLA-A;HLA-B;...
Pathogenic Escherichia coli infection -1.66 3.04e-2 152/197 (77.16%) SEC24A;TUBB2A;IKBKG;...
Cell adhesion molecules -1.66 3.15e-2 118/148 (79.73%) ICAM3;HLA-A;ITGB7;...
Hematopoietic cell lineage -1.69 2.41e-2 90/99 (90.91%) HLA-DPB1;ITGA5;CSF2RA;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -1.71 2.30e-2 79/89 (88.76%) STAT3;JAK2;PTPN11;...
VEGF signaling pathway -1.71 2.40e-2 50/59 (84.75%) CASP9;MAPKAPK3;KDR;...
Antigen processing and presentation -1.73 2.00e-2 60/78 (76.92%) CREB1;NFYA;CD8B;...
Choline metabolism in cancer -1.73 2.04e-2 84/98 (85.71%) SLC22A3;PDGFB;RAC2;...
Fluid shear stress and atherosclerosis -1.74 2.01e-2 123/139 (88.49%) THBD;PTK2;BMPR2;...
Bacterial invasion of epithelial cells -1.74 2.11e-2 59/77 (76.62%) ITGA5;PTK2;ACTB;...
Amoebiasis -1.74 2.15e-2 99/102 (97.06%) RAB7A;CXCL8;ITGB2;...
Chemokine signaling pathway -1.75 2.20e-2 163/192 (84.9%) IKBKG;PLCB1;CXCR3;...
NF-kappa B signaling pathway -1.75 2.26e-2 90/104 (86.54%) IKBKG;TRAF1;CFLAR;...
B cell receptor signaling pathway -1.77 1.84e-2 71/81 (87.65%) NFATC3;MAP2K2;RAC3;...
Type I diabetes mellitus -1.77 1.79e-2 38/43 (88.37%) IFNG;HLA-A;HLA-B;...
Rheumatoid arthritis -1.80 1.37e-2 78/93 (83.87%) CXCL8;ITGB2;TGFB2;...
Transcriptional misregulation in cancer -1.81 1.38e-2 158/192 (82.29%) IL2RB;JUP;CSF1R;...
Acute myeloid leukemia -1.83 9.59e-3 66/67 (98.51%) IKBKG;JUP;CSF1R;...
Inflammatory bowel disease -1.86 8.14e-3 58/65 (89.23%) TGFB2;TLR5;IL4R;...
Osteoclast differentiation -1.89 6.40e-3 117/127 (92.13%) NCF2;CREB1;NFATC1;...
T cell receptor signaling pathway -1.89 7.11e-3 93/104 (89.42%) NFATC3;MAP2K2;CD40LG;...
Malaria -1.90 7.99e-3 44/50 (88%) THBS1;CXCL8;ITGB2;...
Chagas disease -1.92 7.31e-3 93/102 (91.18%) IKBKG;PLCB1;GNAI1;...
Th17 cell differentiation -1.92 8.53e-3 95/107 (88.79%) IL2RB;IKBKG;SMAD4;...
Toll-like receptor signaling pathway -1.93 1.02e-2 94/104 (90.38%) MAP3K8;TLR5;TICAM1;...
Allograft rejection -1.95 1.28e-2 32/38 (84.21%) IFNG;HLA-A;HLA-B;...
Th1 and Th2 cell differentiation -2.04 4.26e-3 80/92 (86.96%) JAK2;STAT1;NOTCH2;...
TNF signaling pathway -2.06 0.00e+0 103/112 (91.96%) CEBPB;MAP3K8;CCL20;...
Asthma -2.31 0.00e+0 25/31 (80.65%) HLA-DPB1;RNASE3;CD40LG;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 12.5uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H